A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab

Peking Union Medical College Hospital500 enrolled

Overview

The purpose of this protocol is to generate a registry of Chinese patients with AL amyloidosis treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

AL Amyloidosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years and older * newly diagnosed or refractory/relapsed AL amyloidosis * treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy Exclusion Criteria: * co-diagnosis of multiple myeloma or Waldenström's macroglobulinemia

Locations (1)

Peking Union Medical College Hospital

Beijing, China

RECRUITING

Outcomes

Primary Outcomes

Hematologic complete response at 3 months

Time frame: 3 months

Central Contacts

Daobin Zhou, MD

CONTACT

69155020 zhoudb@pumch.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.